TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10836659

Group type: EXPERIMENTAL
Intervention: Drospirenone 2 mg/30 microg ethinylestradiol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg/30 microg ethinylestradiol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Drospirenone alone (2 mg and 3 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Drospirenone alone (0.5 mg, 1.0 mg, 2.0 mg, 3.0 mg)
Number of subjects: 100
Study: 9586530

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Rowenta)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Manual toothbrush (Elmex)
Number of subjects: 73
Study: 8145175

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 2431648

Group type: COMPARATOR
Intervention: 0.5% bupivacaine (30 ml) diluted with 0.9% saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (30 ml) diluted with dextran 110
Number of subjects: 50
Study: 30004828

Group type: EXPERIMENTAL
Intervention: Educational intervention based on health beliefs model (HBM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 70
Study: 26993105

Group type: EXPERIMENTAL
Intervention: Calcitonin nasal spray 200 IU/day once a day for 3 months after surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo once a day for 3 months after surgery
Number of subjects: 24
Study: 24884585

Group type: EXPERIMENTAL
Intervention: DHA supplementation (250 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (250 mg of olive oil daily)
Number of subjects: 0
Study: 23136909

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 6537

Group type: COMPARATOR
Intervention: Control group (comparator vaccine)
Number of subjects: 6537
Study: 21029821

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 1289

Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 1289

Group type: COMPARATOR
Intervention: atorvastatin 20 mg
Number of subjects: 1289

Group type: COMPARATOR
Intervention: atorvastatin 40 mg
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1289
Study: 18541203

Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 32
Study: 15996060

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy with adalimumab (7 infusions: Week 0, 2, 4, 6, 8, 10, and 12)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy with adalimumab
Number of subjects: 13

Group type: COMPARATOR
Intervention: Baseline levels of sex hormones in patients with RA
Number of subjects: 13
Study: 12085316

Group type: EXPERIMENTAL
Intervention: Baseline qualitative plasma CMV polymerase chain reaction (PCR) positivity
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Time-updated PCR positivity
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Change in cumulative PCR status
Number of subjects: 378
Study: 10476893

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus tetracycline fibers
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scaling and root planing only
Number of subjects: 30
Study: 8942411

Group type: EXPERIMENTAL
Intervention: Cholesterol-fortified formula
Number of subjects: 3

Group type: COMPARATOR
Intervention: Cholesterol-unfortified formula
Number of subjects: 3

Group type: COMPARATOR
Intervention: Breast-fed
Number of subjects: 3
Study: 2013505

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with metronidazole
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid with metronidazole
Number of subjects: 80
Study: 30947727

Group type: EXPERIMENTAL
Intervention: Deep-ocean mineral water
Number of subjects: 17

Group type: COMPARATOR
Intervention: Mountain spring water
Number of subjects: 17

Group type: COMPARATOR
Intervention: Carbohydrate-based sports drink
Number of subjects: 17
Study: 28598899

Group type: EXPERIMENTAL
Intervention: venlafaxine ER 75-225 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 25462210

Group type: EXPERIMENTAL
Intervention: Octreotide (600 μg/24 hours by infusion)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 23458319

Group type: EXPERIMENTAL
Intervention: Internet-delivered transdiagnostic cognitive behavioural therapy (iCBT)
Number of subjects: 129
Study: 21411655

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg naloxone
Number of subjects: 0
Study: 19438775

Group type: EXPERIMENTAL
Intervention: Pump flow rate calculated on ideal BMI of 25
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pump flow rate set on 2.4 L/min/m(2) of body surface area
Number of subjects: 0
Study: 17605563

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 87
Study: 15008675

Group type: EXPERIMENTAL
Intervention: Nonverbal serial-order task training
Number of subjects: 5
Study: 11480809

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine and 1% thymol varnish
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 25
Study: 9570197

Group type: EXPERIMENTAL
Intervention: Cocaine hydrochloride 1 mg/min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 7978099

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.25 mg bid
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 2558365

Group type: EXPERIMENTAL
Intervention: Neurokinin A (0.02 ml, 10(‐5)M)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 1201769

Group type: EXPERIMENTAL
Intervention: Intravenous fat solution containing 40 g of soy bean oil
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral fat solution containing 40 g of soy bean oil
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intraduodenal fat solution containing 40 g of soy bean oil
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intravenous, oral, and intraduodenal fat administration
Number of subjects: 35
Study: 30084112

Group type: EXPERIMENTAL
Intervention: GEMI/ROSU FDC (gemigliptin 50 mg and rosuvastatin 20 mg)
Number of subjects: 290

Group type: COMPARATOR
Intervention: GEMI (gemigliptin 50 mg)
Number of subjects: 290

Group type: COMPARATOR
Intervention: ROSU (rosuvastatin 20 mg)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 290
Study: 28608666

Group type: EXPERIMENTAL
Intervention: Kistinox® Forte, 1 sachet per day during the first 10 days of the month for 3 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 150
Study: 25343689

Group type: EXPERIMENTAL
Intervention: Text message reminders (12 messages over 4 weeks, 1 message for 8 weeks thereafter)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 50
Study: 23518286

Group type: EXPERIMENTAL
Intervention: HF rTMS (20 Hz, 10 Hz, sham)
Number of subjects: 66
Study: 20566267

Group type: EXPERIMENTAL
Intervention: Five-point scale with descriptors for all scale points
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 10-point scale with descriptors only at the end points
Number of subjects: 1000
Study: 19107051

Group type: EXPERIMENTAL
Intervention: 400 microg of dexamethasone administered intravitreally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids and antibiotics (general reference)
Number of subjects: 0
Study: 16418097

Group type: EXPERIMENTAL
Intervention: Long-intervention group (16-hour workshop)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Short-intervention group (2-hour class)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (toxicology program)
Number of subjects: 83
Study: 12919154

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.02 mg/kg orally at -90 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11887256

Group type: EXPERIMENTAL
Intervention: Exposure to psychiatric nursing theory and practice (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exposure to psychiatric nursing theory and practice)
Number of subjects: 0
Study: 8740084

Group type: EXPERIMENTAL
Intervention: Tuaminoheptane/N-acetyl-cysteine (THS/NAC)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 18
Study: 1342906

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 0.1% solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1% solution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Piroxicam 0.5% solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 4058820

Group type: EXPERIMENTAL
Intervention: Low Tucker‐McLane forceps
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Silastic vacuum extraction system
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mityvac vacuum extractor
Number of subjects: 118
Study: 27940899

Group type: EXPERIMENTAL
Intervention: In-depth recommendations by the physician reinforced with SMS messages (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Minimal recommendations by the physician (Group 1)
Number of subjects: 40
Study: 25941207

Group type: EXPERIMENTAL
Intervention: Family-based intervention in grade 6 and school-based drug preventive intervention in grade 7
Number of subjects: 424

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Family-based intervention and school-based drug preventive intervention
Number of subjects: 424
Study: 25027229

Group type: EXPERIMENTAL
Intervention: Intervention group (feedback information programs directed to GPs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study: 22694350

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing tablets
Number of subjects: 40
Study: 20228677

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (16 mmol bolus, 8 mmol/hr infusion for 10 days)
Number of subjects: 110
Study: 18771581

Group type: EXPERIMENTAL
Intervention: Finger Trainer (20 min every work day for four weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bimanual group therapy (20 min every work day for four weeks)
Number of subjects: 10
Study: 15924667

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Radiotherapy (C + R group)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Radiotherapy (R group)
Number of subjects: 186
Study: 14676046

Group type: EXPERIMENTAL
Intervention: Rotigotine 13.5 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Rotigotine 18.0 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 11014414

Group type: EXPERIMENTAL
Intervention: High-dose LY293558 (1.2 mg/kg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (30 mg)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low-dose LY293558 (0.4 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 9006245

Group type: EXPERIMENTAL
Intervention: Health education materials written at a lower reading level (3rd-grade level)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Health education materials written at a higher reading level (10th-grade level)
Number of subjects: 252
Study: 1620773

Group type: EXPERIMENTAL
Intervention: Talking therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 37
Study: 6375760

Group type: EXPERIMENTAL
Intervention: Daunorubicin (45 mg/m2 IV on days 1, 2, 3)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Vincristine, prednisone, and L‐asparaginase alone
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Daunorubicin (in subsequent nonrandomized treatment)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Maintenance therapy (6-mercaptopurine and methotrexate with periodic reinforcement with vincristine and prednisone)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Complete response
Number of subjects: 177
Study: 30755061

Group type: EXPERIMENTAL
Intervention: Evolocumab (PCSK9 inhibitor)
Number of subjects: 895
Study: 28004321

Group type: COMPARATOR
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Combined MC and LC
Number of subjects: 109
Study: 26003770

Group type: EXPERIMENTAL
Intervention: External cold and vibration via Buzzy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study: 23178050

Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation
Number of subjects: 26957

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 26957

Group type: COMPARATOR
Intervention: Nondepressed cohort
Number of subjects: 26957
Study: 22047557

Group type: EXPERIMENTAL
Intervention: Ivacaftor (150 mg every 12 hours)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 20092592

Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05%
Number of subjects: 44

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 44
Study: 17061966

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed group (n = 68)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Physician-managed group (n = 69)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Physician-managed group
Number of subjects: 141
Study: 15014543

Group type: EXPERIMENTAL
Intervention: Warm-up exercise prior to SAP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resting prior to exposures
Number of subjects: 20
Study: 12170942

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 52

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 52
Study: 9781946

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Prolonged chemotherapy
Number of subjects: 465
Study: 7529924

Group type: EXPERIMENTAL
Intervention: Iloprost treatment (10 micrograms/ml for the first 3 days, then 40 micrograms/ml for the remaining period, applied daily for 8 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 99
Study: 3296624

Group type: EXPERIMENTAL
Intervention: Oxiracetam (2.4 mg per day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 29323628

Group type: EXPERIMENTAL
Intervention: CONTECI telehealth program (Intervention Arm)
Number of subjects: 150

Group type: COMPARATOR
Intervention: In-person patient visits (Control Arm)
Number of subjects: 150
Study: 28302573

Group type: EXPERIMENTAL
Intervention: 10-min low-to-moderate intensity stair walking
Number of subjects: 18

Group type: COMPARATOR
Intervention: 50mg caffeine capsule
Number of subjects: 18

Group type: COMPARATOR
Intervention: Flour (placebo) capsule
Number of subjects: 18
Study: 26252477

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (ATRT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control
Number of subjects: 196
Study: 23819816

Group type: EXPERIMENTAL
Intervention: Values-focused intervention with a third day of training and 12 months of coaching
Number of subjects: 200

Group type: COMPARATOR
Intervention: Implementation training (control group)
Number of subjects: 200
Study: 22240886

Group type: EXPERIMENTAL
Intervention: Topically applied calcium glycerophosphate (CGP) 10% in an aqueous lotion, applied once daily for 42 days starting at the third postoperative day.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 20
Study: 18847321

Group type: EXPERIMENTAL
Intervention: 20 microg (800 IU) vitamin D supplementation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10 microg (400 IU) vitamin D supplementation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16581474

Group type: EXPERIMENTAL
Intervention: Quantitative adenosine real-time myocardial contrast echocardiography (MCE)
Number of subjects: 43
Study: 14675309

Group type: EXPERIMENTAL
Intervention: FACT/GOG-Ntx questionnaire for patients with known neurotoxicities
Number of subjects: 0

Group type: COMPARATOR
Intervention: FACT/GOG-Ntx questionnaire for chemotherapy-naive women
Number of subjects: 0
Study: 10838234

Group type: EXPERIMENTAL
Intervention: Bronze level tuition
Number of subjects: 495

Group type: COMPARATOR
Intervention: Conventional course
Number of subjects: 495
Study: 9330135

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Plain Radiography
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both CT and Plain Radiography
Number of subjects: 19
Study: 8471588

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Dihydrocodeine 60 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Dihydrocodeine 30 mg
Number of subjects: 68
Study: 3545106

Group type: EXPERIMENTAL
Intervention: Aztreonam and Clindamycin (A/C)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Gentamicin and Clindamycin (G/C)
Number of subjects: 84
Study: 29552916

Group type: EXPERIMENTAL
Intervention: Intermittent low-dose urokinase (UK) 10,000 U/kg once a day for 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Alteplase (rt-PA) 50 mg by intravenous injection within 2 hours of admission
Number of subjects: 48
Study: 27135252

Group type: EXPERIMENTAL
Intervention: Permissive parenting (lax-inconsistent disciplining) by parents
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Father's unsafe behaviors (modeling)
Number of subjects: 67
Study: 24972101

Group type: EXPERIMENTAL
Intervention: Video‐feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP‐SD)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 43
Study: 22643798

Group type: EXPERIMENTAL
Intervention: Cemented, unconstrained, cruciate‐retaining TKA with a rotating platform (normal group with less than 10° rotational mismatch)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cemented, unconstrained, cruciate‐retaining TKA with a rotating platform (group with more than 10° rotational mismatch)
Number of subjects: 80
Study: 21110263

Group type: EXPERIMENTAL
Intervention: Subjects with MS (RRMS and SPMS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Subjects with RRMS
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control subjects without MS
Number of subjects: 96
Study: 17997100

Group type: EXPERIMENTAL
Intervention: Flexion splinting (70 degrees of flexion over an inactive CPM machine for 24 hours post-operation)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Extension splinting (full extension for the first 24 hours post-operation)
Number of subjects: 95
Study: 16449270

Group type: EXPERIMENTAL
Intervention: 4 week supervised pulmonary rehabilitation (PR) programme
Number of subjects: 100

Group type: COMPARATOR
Intervention: 7 week supervised pulmonary rehabilitation (PR) programme
Number of subjects: 100
Study: 12593590

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Open flap debridement (Control)
Number of subjects: 9
Study: 10701893

Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin therapy (IVIG) 2 g/kg bodyweight
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9554161

Group type: EXPERIMENTAL
Intervention: Clomiphene 100 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clomiphene 150 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exogenous oestrogens
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clomiphene 50 mg/day
Number of subjects: 6
Study: 8211584

Group type: EXPERIMENTAL
Intervention: Spontaneous placental detachment, in situ uterine repair
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Spontaneous placental detachment, exteriorized uterine repair
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Manual placental removal, in situ uterine repair
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Manual placental removal, exteriorized uterine repair
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spontaneous placental detachment (groups 1 and 2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual placental removal (groups 3 and 4)
Number of subjects: 100
Study: 3551011

Group type: EXPERIMENTAL
Intervention: intravenous atropine + inhaled oxitropium bromide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: intravenous atropine alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: intravenous salbutamol + inhaled salbutamol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: intravenous salbutamol alone
Number of subjects: 24
Study: 31046594

Group type: EXPERIMENTAL
Intervention: Keeping a private gratitude journal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overtly expressing gratitude to the other
Number of subjects: 100

Group type: COMPARATOR
Intervention: Perceived wife's expressed gratitude as less sincere
Number of subjects: 100
Study: 29928924

Group type: EXPERIMENTAL
Intervention: EDS-FLU (93, 186, or 372 μg)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: EDS-FLU (all doses)
Number of subjects: 323

Group type: COMPARATOR
Intervention: EDS-placebo
Number of subjects: 323
Study: 28160585

Group type: EXPERIMENTAL
Intervention: Topical TGO gel
Number of subjects: 180

Group type: COMPARATOR
Intervention: Triamcinolone acetonide pomade
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 26492839

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 22